Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients
2008

Clinical Experience with TTP-HUS: 24-Year Study of 178 Patients

Sample size: 178 publication 10 minutes Evidence: moderate

Author Information

Author(s): Levandovsky Mark, Harvey Danielle, Lara Primo, Wun Ted

Primary Institution: Weill School of Medicine, Cornell University

Hypothesis

Can clinical or laboratory characteristics predict important short- and long-term outcomes in patients with TTP-HUS?

Conclusion

Plasma exchange therapy produced high response and survival rates in patients with TTP-HUS, with renal insufficiency associated with a decreased risk of relapse.

Supporting Evidence

  • 30-day mortality was 16%, with 27 patients dying within this period.
  • Plasma exchange was the principal treatment for 171 patients, with a mean of 8 exchanges.
  • The overall 5-year survival rate was estimated at 55%.

Takeaway

This study looked at 178 patients with a serious blood condition and found that a specific treatment helped many of them survive and recover.

Methodology

Retrospective cohort study analyzing clinical and laboratory characteristics of patients treated with plasma exchange.

Potential Biases

Recall bias may affect follow-up data due to reliance on patient and physician interviews.

Limitations

The study is retrospective, which may introduce biases, and it spans 24 years, potentially affecting treatment consistency.

Participant Demographics

Predominantly female (68%), median age 49 years, with a diverse ethnic background reflective of California's population.

Statistical Information

P-Value

0.04

Confidence Interval

95% CI: 1.003–1.16

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1756-8722-1-23

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication